

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
NMPA IND CLEARANCE FOR HBM9378/SKB378 IN THE TREATMENT OF
COPD

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Group has been granted the clearance of the Investigational New Drug (“**IND**”) from the Centre for Drug Evaluation of the National Medical Products Administration of China (the “**NMPA**”) for HBM9378/SKB378 (also known as WIN378), a fully human antibody targeting thymic stromal lymphopoietin (“**TSLP**”), to initiate the clinical trial for the treatment of chronic obstructive pulmonary disease (“**COPD**”).

Reference is made to the Company’s announcement dated 10 January 2025 in relation to that the Company and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“**Kelun-Biotech**”, stock code: 06990) entered into a global licensing agreement (excluding Greater China and several Southeast and West Asian countries) with Windward Bio AG for HBM9378/SKB378. Under the terms of the agreement, the Company and Kelun-Biotech are eligible to receive a total of up to US\$970 million upfront and milestone payments as well as tiered single to double digits royalty payments on net sales. The US\$45 million upfront and near-term milestone payments include both cash payment and an equity interest in the parent company of Windward Bio.

About HBM9378/SKB378

HBM9378/SKB378 (also known as WIN378) is a co-development project conducted by the Company and Kelun-Biotech who together equally share the rights in Greater China and several Southeast and West Asian countries. HBM9378/SKB378 is a fully human monoclonal antibody against TSLP generated from two heavy chains and two light chains (H2L2) platform. It inhibits the TSLP mediated signaling pathway by blocking the interaction between TSLP and TSLP receptor, its long half-life optimization and outstanding biophysical properties support the favorable dosing advantage. Currently, the Company has completed the Phase I trial in China under IND for the treatment of moderate-to-severe asthma.

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market HBM9378/SKB378. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 5 February 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive directors.